Mallinckrodt plc (MNK) : $12.35 million worth of transactions were on upticks in Mallinckrodt plc (MNK), compared to $10.91 million on downticks. The ratio between the two was 1.13, whereas, the net money flow stood at a healthy $1.44 million on Fridays session. The consistent buying on upticks in the stock accounted for $0million worth of trades. The total money flow into the stock stood at $0 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -1.39%. The stock was trading at $66.59, with a drop of $0.94 over the previous days close. The stock recorded 6.63% for the week.
Mallinckrodt plc (MNK) : 11 investment research analysts covering Mallinckrodt plc (MNK) have an average price target of $90.27 for the near short term. The highest target price given by the Brokerage Firm to the stock is $115 and the lowest target is $75 for the short term. Analysts expect the variance to be within $11.52 of the average price.
Mallinckrodt plc (NYSE:MNK): On Fridays trading session , Opening price of the stock was $67.53 with an intraday high of $67.997. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $65.85. However, the stock managed to close at $66.49, a loss of 1.54% for the day. On the previous day, the stock had closed at $67.53. The total traded volume of the day was 945,199 shares.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CFO of Mallinckrodt Plc, Harbaugh Matthew K, had purchased 500 shares in a transaction dated on May 10, 2016. The transaction was executed at $59.37 per share with total amount equaling $29,685.
Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.